Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines

Jinkyoung Kim, Ji-Yun Lee, Soon Young Jang, Chungyeul Kim, Yoojin Choi, Aeree Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Acquisition of tamoxifen resistance (TR) during anti-estrogenic therapy using tamoxifen is a major obstacle in the treatment of estrogen receptor (ER)-positive breast cancer. As a biguanide derivative, metformin is commonly used to treat type II diabetes. It has recently emerged as a potential anticancer agent. The objective of the present study was to investigate the anticancer activity of metformin in relation to ERα expression and its signaling pathway in ERα-positive MCF-7 and MDA-MB-361 breast cancer cells as well as TR MCF-7 breast cancer cells. Metformin inhibited both protein and mRNA levels of ERα in the presence or absence of estrogen (E2) in the MCF-7, TR MCF-7 and MDA-MB-361 cells. Metformin repressed E2-inducible estrogen response element (ERE) luciferase activity, protein levels and mRNA levels of E2/ERα-regulated genes [including c-Myc, cyclin D1, progesterone receptor (PR) and pS2] to a greater degree than tamoxifen, resulting in inhibition of cell proliferation of MCF-7, TR MCF-7 and MDA-MB-361 cells. Collectively, our results suggest that one of the anticancer mechanisms of metformin could be attributable to the repression of expression and transcriptional activity of ERα. Metformin may be a good therapeutic agent for treating ERα-positive breast cancer by inhibiting the expression and function of ERα. In addition, metformin may be useful to treat tamoxifen-resistant breast cancer.

Original languageEnglish
Pages (from-to)2553-2560
Number of pages8
JournalOncology Reports
Volume35
Issue number5
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Metformin
Tamoxifen
Estrogen Receptors
Breast Neoplasms
Cell Line
Estrogens
Biguanides
Messenger RNA
myc Genes
Cyclin D1
Response Elements
Progesterone Receptors
Luciferases
Antineoplastic Agents
Type 2 Diabetes Mellitus
Proteins
Cell Proliferation
Therapeutics

Keywords

  • Anti-estrogen therapy
  • Breast cancer
  • Estrogen receptor
  • Estrogen response element
  • Metformin
  • Tamoxifen resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. / Kim, Jinkyoung; Lee, Ji-Yun; Jang, Soon Young; Kim, Chungyeul; Choi, Yoojin; Kim, Aeree.

In: Oncology Reports, Vol. 35, No. 5, 01.05.2016, p. 2553-2560.

Research output: Contribution to journalArticle

Kim, Jinkyoung ; Lee, Ji-Yun ; Jang, Soon Young ; Kim, Chungyeul ; Choi, Yoojin ; Kim, Aeree. / Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. In: Oncology Reports. 2016 ; Vol. 35, No. 5. pp. 2553-2560.
@article{489223ebddc3477198fe7a499cc89d93,
title = "Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines",
abstract = "Acquisition of tamoxifen resistance (TR) during anti-estrogenic therapy using tamoxifen is a major obstacle in the treatment of estrogen receptor (ER)-positive breast cancer. As a biguanide derivative, metformin is commonly used to treat type II diabetes. It has recently emerged as a potential anticancer agent. The objective of the present study was to investigate the anticancer activity of metformin in relation to ERα expression and its signaling pathway in ERα-positive MCF-7 and MDA-MB-361 breast cancer cells as well as TR MCF-7 breast cancer cells. Metformin inhibited both protein and mRNA levels of ERα in the presence or absence of estrogen (E2) in the MCF-7, TR MCF-7 and MDA-MB-361 cells. Metformin repressed E2-inducible estrogen response element (ERE) luciferase activity, protein levels and mRNA levels of E2/ERα-regulated genes [including c-Myc, cyclin D1, progesterone receptor (PR) and pS2] to a greater degree than tamoxifen, resulting in inhibition of cell proliferation of MCF-7, TR MCF-7 and MDA-MB-361 cells. Collectively, our results suggest that one of the anticancer mechanisms of metformin could be attributable to the repression of expression and transcriptional activity of ERα. Metformin may be a good therapeutic agent for treating ERα-positive breast cancer by inhibiting the expression and function of ERα. In addition, metformin may be useful to treat tamoxifen-resistant breast cancer.",
keywords = "Anti-estrogen therapy, Breast cancer, Estrogen receptor, Estrogen response element, Metformin, Tamoxifen resistance",
author = "Jinkyoung Kim and Ji-Yun Lee and Jang, {Soon Young} and Chungyeul Kim and Yoojin Choi and Aeree Kim",
year = "2016",
month = "5",
day = "1",
doi = "10.3892/or.2016.4675",
language = "English",
volume = "35",
pages = "2553--2560",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines

AU - Kim, Jinkyoung

AU - Lee, Ji-Yun

AU - Jang, Soon Young

AU - Kim, Chungyeul

AU - Choi, Yoojin

AU - Kim, Aeree

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Acquisition of tamoxifen resistance (TR) during anti-estrogenic therapy using tamoxifen is a major obstacle in the treatment of estrogen receptor (ER)-positive breast cancer. As a biguanide derivative, metformin is commonly used to treat type II diabetes. It has recently emerged as a potential anticancer agent. The objective of the present study was to investigate the anticancer activity of metformin in relation to ERα expression and its signaling pathway in ERα-positive MCF-7 and MDA-MB-361 breast cancer cells as well as TR MCF-7 breast cancer cells. Metformin inhibited both protein and mRNA levels of ERα in the presence or absence of estrogen (E2) in the MCF-7, TR MCF-7 and MDA-MB-361 cells. Metformin repressed E2-inducible estrogen response element (ERE) luciferase activity, protein levels and mRNA levels of E2/ERα-regulated genes [including c-Myc, cyclin D1, progesterone receptor (PR) and pS2] to a greater degree than tamoxifen, resulting in inhibition of cell proliferation of MCF-7, TR MCF-7 and MDA-MB-361 cells. Collectively, our results suggest that one of the anticancer mechanisms of metformin could be attributable to the repression of expression and transcriptional activity of ERα. Metformin may be a good therapeutic agent for treating ERα-positive breast cancer by inhibiting the expression and function of ERα. In addition, metformin may be useful to treat tamoxifen-resistant breast cancer.

AB - Acquisition of tamoxifen resistance (TR) during anti-estrogenic therapy using tamoxifen is a major obstacle in the treatment of estrogen receptor (ER)-positive breast cancer. As a biguanide derivative, metformin is commonly used to treat type II diabetes. It has recently emerged as a potential anticancer agent. The objective of the present study was to investigate the anticancer activity of metformin in relation to ERα expression and its signaling pathway in ERα-positive MCF-7 and MDA-MB-361 breast cancer cells as well as TR MCF-7 breast cancer cells. Metformin inhibited both protein and mRNA levels of ERα in the presence or absence of estrogen (E2) in the MCF-7, TR MCF-7 and MDA-MB-361 cells. Metformin repressed E2-inducible estrogen response element (ERE) luciferase activity, protein levels and mRNA levels of E2/ERα-regulated genes [including c-Myc, cyclin D1, progesterone receptor (PR) and pS2] to a greater degree than tamoxifen, resulting in inhibition of cell proliferation of MCF-7, TR MCF-7 and MDA-MB-361 cells. Collectively, our results suggest that one of the anticancer mechanisms of metformin could be attributable to the repression of expression and transcriptional activity of ERα. Metformin may be a good therapeutic agent for treating ERα-positive breast cancer by inhibiting the expression and function of ERα. In addition, metformin may be useful to treat tamoxifen-resistant breast cancer.

KW - Anti-estrogen therapy

KW - Breast cancer

KW - Estrogen receptor

KW - Estrogen response element

KW - Metformin

KW - Tamoxifen resistance

UR - http://www.scopus.com/inward/record.url?scp=84964091199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964091199&partnerID=8YFLogxK

U2 - 10.3892/or.2016.4675

DO - 10.3892/or.2016.4675

M3 - Article

C2 - 26986571

AN - SCOPUS:84964091199

VL - 35

SP - 2553

EP - 2560

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -